The r&d sweet spot: quoin pharmaceuticals delivering value-based drug development through rare and orphan disease therapeutics

New york, new york--(newsfile corp. - december 14, 2021) - pcg digital -- drug development is complex, lengthy and expensive, and not without its risks. bringing a drug to market takes years, with costs quickly running into hundreds of millions of dollars, and no promise of success at the end of it all. rare and orphan indications provide an r&d 'sweet spot' for biopharmaceutical companies pursuing drug development. drugs for rare diseases have a high...
QNRX Ratings Summary
QNRX Quant Ranking